Skip to main content
. 2014 Dec 10;6(4):2009–2022. doi: 10.18632/oncotarget.2987

Figure 2. NRG1, EGF and HGF attenuate FGFR2 kinase inhibition in GC cells with FGFR2 amplification.

Figure 2

A) SNU16 and B) KATOIII cells were treated with increasing doses of AZD4547, either alone or with NRG1, EGF, HGF, IGF-1 and PDGF (50 ng/mL) for 72 hours and then analyzed by CCK-8 assay. Data (n = 3) are presented as mean ± SD. * p < 0.01 compared with the AZD4547-treated control group. Cells were treated with 10 nM of AZD4547 for 24 hours, then stimulated with ligands for 30 minutes before whole cell lysates were collected and analyzed by western blot. HER3, MET and EGFR activation attenuated AZD4547 kinase inhibition by restoring MAPK and/or AKT downstream signaling.